SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Mevion partners with Philips to improve proton therapy treatment New technology only takes a few seconds to scan tumor

Kentucky Trailer acquires Advanced Mobility to expand medical footprint Together they look toward a greater international presence

Screening with tomo and mammo leads to 405 fewer false positives per 1,000 women The cost of the two is relative to cost of mammo alone

Comparing catheters for early stage breast brachytherapy Is the treatment underutilized? The BC5 Project thinks so.

Health Gorilla Marketplace expands in effort to demystify ACO and IPA options Version 2.0 adds seven new vendor categories to its market reach

Siemens' new MR kit may reduce pediatric anxiety and need for sedation Could lead to reduced costs and increased efficiency

400 experts gather at Focused Ultrasound Foundation's annual meeting 200 scientific presentations show promising new research

380 hospitals execs weigh in on the future The quest to provide better care with fewer resources

Companies develop pediatric medical devices to compete for $50,000 prize Will the smallest of patients finally have more options?

New imaging method may detect cancer earlier Will shortwave infrared be a bright spot?

IBA spin-off, Novation ink PET radiopharmaceutical deal

by Brendon Nafziger , DOTmed News Associate Editor
Ion Beam Applications S.A.'s newly spun-off radiopharmaceutical wing IBA Molecular has inked a five-year deal with group purchasing organization Novation LLC to supply its member health care facilities with PET radiotracers.

Under the deal, announced Monday, IBA Molecular will supply imaging agents, including 18-Fluorodeoxyglucose, as well as provide educational and training services. The contract took effect July 1. Terms of the deal weren't disclosed.

Story Continues Below Advertisement

Delivering on Dose Reduction Promises

Dr. Steven Mendelsohn of Zwanger-Pesiri Radiology, explains his commitment to dose reduction and why he believes a change in attitudes will be driven by patients rather than radiology professionals. Click to read more>>>



IBA Molecular has 54 PET isotope facilities in Europe, North America and Asia. It also delivers agents for SPECT imaging worldwide.

SK Capital Partners holds a controlling stake in IBA Molecular, which was spun off from its Belgian parent company, which retains a minority stake, in April.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED